Everything below concerns lipolysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-22. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Chloroformates are a class of organic compounds with the formula ROC(O)Cl. They are formally esters of chloroformic acid. Most are colorless, volatile liquids that degrade in moist air. Important chloroformate esters include 4-nitrophenyl chloroformate, fluorenylmethyloxycarbonylchloride, benzyl chloroformate and ethyl chloroformate. A simple example is methyl chloroformate, which is also commercially available. Chloroformates are used as reagents in organic chemistry. For example, benzyl chloroformate is used to introduce the Cbz (carboxybenzyl) protecting group and fluorenylmethyloxycarbonyl chloride is used to introduce the FMOC protecting group. Chloroformates are popular in the field of chromatography as derivatization agents. They convert polar compounds into less polar more volatile derivatives. In this way, chloroformates enable relatively simple transformation of large array of metabolites (aminoacids, amines, carboxylic acids, phenols) for analysis by gas chromatography / mass spectrometry.
In November 2022, Cerebras announced a partnership with Cirrascale Cloud Services to provide a flat-rate "pay-per-model" compute time for its Cerebras AI Model Studio. In November 2022, the National Energy Technology Laboratory (NETL) set milestones using Cerebras products. In November 2022, Argonne National Laboratory won the 2022 Gordon Bell Special Prize for COVID-19 research by using the CS-2 as well as products from Nvidia and Hewlett-Packard to transform large language models to analyze and predict variants of SARS-CoV-2. In July 2023, G42 agreed to pay around $100 million to purchase the first of potentially nine supercomputers from Cerebras. The first computer, Condor Galaxy 1 (CG-1), is capable of 4 quintillion floating-point operations per second (4 exaflops) of compute and contains 54 million cores. In November 2023, the second computer, the Condor Galaxy 2 (CG-2), was announced, with similar specifications as the CG-1. In March 2024, the companies broke ground on the Condor Galaxy 3 (CG-3), which can reach 8 exaFLOPs of performance and contains 58 million AI-optimized cores. In August 2023, Cerebras, the Mohamed bin Zayed University of Artificial Intelligence, and G42 subsidiary Inception launched Jais, a large language model. In March 2024, Cerebras introduced Wafer Scale Engine (WSE-3) architecture, a 5nm-based chip hosting 4 trillion transistors and 900,000 AI-optimized cores, and the basis for the CS-3. It has twice the performance of CS-2. The CS-3 was named to the list of the "best inventions of 2024" by Time.
This contradicts information published earlier in a Wired article, which states that the hyperthymesiac Jill Price had been brain scanned and her "hippocampus and prefrontal cortex were reportedly normal", suggesting that these regions of the brain do not need to be different for hyperthymesia to occur. Significant debate also exists over the limits of memory capacity. Some are of the view that the brain contains so many potential synaptic connections that, in theory at least, no practical limit exists to the number of long-term memories that the brain can store. In 1961, Wilder Penfield reported that specific stimulation of the temporal lobes resulted in vivid recollection of memories. He concluded that our brains were making "continuous, effortless, video-like recordings" of our experiences, but that these records are not consciously accessible to us. However, a study published in the Proceedings of the National Academy of Sciences suggested that hyperthymesiacs may reconstruct memories from traces and incorporate post-event information and associations—a finding at odds with Penfield's video-like recording analogy.
Sources: en.wikipedia.org
=== Monoclonal antibodies targeting the CGRP molecule === Eptinezumab (ALD403) is approved for prevention of migraine. Fremanezumab (TEV-48125) is approved for prevention of migraine. Galcanezumab (LY2951742) is approved for prevention of migraine and cluster headaches.
Urticaria is a vascular reaction of the skin characterized by the appearance of wheals, which are firm, elevated swellings of the skin. Angioedema, which can occur alone or with urticaria, is characterized by a well-defined, edematous swelling that involves subcutaneous tissues, abdominal organs, or upper airway.
== Early life == The daughter of Michael and Bonita Pressdee, she was born on August 28, 1982, and is the oldest of two children. From 2003 to 2004, she attended the Community College of Allegheny County but did not graduate. She later became a registered veterinary technician before returning to obtain a nursing degree.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.